The Latest Thinking
- May 15, 2019
- Researchers pinpoint why lymphoma patients may become resistant to specific therapy, identify strategy to overcome it
- April 23, 2019
- Researchers devise a progression risk-based classification for patients with asymptomatic Waldenström macroglobulinemia
- April 16, 2019
- Loss of a DNA repair system creates a unique vulnerability in many cancer types
- March 26, 2019
- Combination of PARP inhibitor and targeted therapy significantly outperforms PARP inhibitor alone in patients with chemotherapy-resistant ovarian cancer
What is Profile?
Profile, launched by scientists at Dana-Farber/Brigham and Women’s Cancer Center and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, is one of the nation's most comprehensive precision cancer medicine research initiatives.
Find Clinical Trials
To find clinical trials that focus on targeted therapies, use the pulldown menus below or enter a term in the search box.
Request a Consultation
To schedule a consultation with an oncologist at Dana-Farber/Brigham and Women's Cancer Center, please call one of our experienced appointment coordinators.
What is Profile?
Profile, launched by scientists at Dana-Farber/Brigham and Women’s Cancer Center and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, is one of the nation's most comprehensive precision cancer medicine research initiatives.
Find Clinical Trials
To find clinical trials that focus on targeted therapies, use the pulldown menus below or enter a term in the search box.
Request a Consultation
To schedule a consultation with an oncologist at Dana-Farber/Brigham and Women's Cancer Center, please call one of our experienced appointment coordinators.
The Latest Thinking
- May 15, 2019
- Researchers pinpoint why lymphoma patients may become resistant to specific therapy, identify strategy to overcome it
- April 23, 2019
- Researchers devise a progression risk-based classification for patients with asymptomatic Waldenström macroglobulinemia
- April 16, 2019
- Loss of a DNA repair system creates a unique vulnerability in many cancer types
- March 26, 2019
- Combination of PARP inhibitor and targeted therapy significantly outperforms PARP inhibitor alone in patients with chemotherapy-resistant ovarian cancer